Aim To determine the antiobesity effect and safety of glucagon-like peptide-1 receptor
agonist (GLP-1RA) including liraglutide, exenatide and semaglutide treatment in …

Clinical trials have investigated the weight loss effect of glucagon‐like peptide‐1 receptor
agonists (GLP‐1 RA) in adults with obesity without diabetes mellitus, but results for weight …

Objective To determine effects of glucagon-like peptide-1 (GLP-1) receptor agonists on≥
5% or≥ 10% weight loss in overweight or obese patients with or without type 2 diabetes …

ABSTRACT Introduction Glucagon-like peptide-1 (GLP-1) is an endogenous peptide which
is secreted by enteroendocrine L cells, GLP-1 receptor agonists (GLP-1 RAs) can exhibit …

Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are new drugs for the
treatment of obesity. Objective To assess the weight-loss effects of GLP-1RAs in the …

Purpose The effect and safety of Semaglutide and Liraglutide on weight loss in people with
obesity or overweight were evaluated by a Network Meta-Analysis system to provide an …

Objective To compare the efficacy and safety between and within glucagon-like peptide-1
receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT-2is) in …

Objective To evaluate the comparative efficacy and safety of glucagon-like peptide-1
receptor agonists (GLP-1RAs) on glycaemic control, body weight, and lipid profile in adults …

Obesity is a chronic disease associated with many complications. Weight loss of 5–15% can
improve many obesity-related complications. Despite the benefits of weight reduction, there …

The prevalence of obesity has increased dramatically in recent decades, both in the US and
worldwide. Pharmacotherapy can augment the weight-reducing effects of lifestyle …